title: Production of anti-endothelial cell antibodies by coculture of EBV-infected human B cells with endothelial cells.
abstract: Vascular endothelial cells are suspected of being the target of autoimmune processes seen in many connective tissue diseases and in systemic vasculitis as evidenced by the detection of circulating autoantibodies against endothelial cell antigens. In order to select B cells recognizing endothelial cells antigens, Epstein-Barr virus (EBV)-infected B cells, obtained from one patient presenting a systemic vasculitis, were cocultured with human endothelial cells concurrently with a human endothelial cell line (EC-pSV1 cells). This coculture consisted of a first step of expansion of B cells specifically selected by adherence onto human umbilical vein endothelial cells (HUVEC). The adherence of selected B cells was specific to endothelial cells because no rosette formation around control cells (HeLa cells or COS cells) was observed. Adherent B cells were cloned by limiting dilution by coculture onto EC-pSV1 cells and screened for anti-HUVEC antibody production by endothelial cell ELISA. An increase in anti-HUVEC antibody production of IgM isotype was detected by endothelial cell ELISA, peaking at Day 9 and remaining constantly elevated, relative to B cell expansion. Among 21 B cell lines producing IgM, 6 presented high levels of anti-HUVEC antibodies, whereas 1 of 52 B cells cloned without EC-pSV1 cells showed such antibody production. Anti-HUVEC antibody production and B cell proliferation were dependent on the presence of endothelial cells. Two of these 6 B cell lines produced antibodies directed against an endothelial cell antigen with an apparent molecular weight of 192 kDa as determined by immunoblotting analysis. Our results demonstrate that adherence of EBV-infected B cells to endothelial cells and further cloning by adherence can efficiently select anti-HUVEC antibody-producing human B cells and might help to define antigens potentially involved in autoimmune diseases.
authors.affiliation: Contrat Jeune Formation (INSERM 90-06), Institut Pasteur, Lille, France.
authors.forename: Y
authors.initials: Y
authors.lastname: Delneste
authors.forename: P
authors.initials: P
authors.lastname: Lassalle
authors.forename: P
authors.initials: P
authors.lastname: Jeannin
authors.forename: L
authors.initials: L
authors.lastname: Mannessier
authors.forename: J P
authors.initials: JP
authors.lastname: Dessaint
authors.forename: M
authors.initials: M
authors.lastname: Joseph
authors.forename: A B
authors.initials: AB
authors.lastname: Tonnel
mesh_terms: D000917:Antibody Formation; D001323:Autoantibodies / Q000096:biosynthesis*; D001324:Autoantigens / Q000737:chemistry; D001402:B-Lymphocytes / Q000276:immunology*; D002472:Cell Transformation, Viral; D002478:Cells, Cultured; D004730:Endothelium, Vascular / Q000276:immunology*; D000939:Epitopes; D004854:Herpesvirus 4, Human; D006801:Humans; D066298:In Vitro Techniques; D008213:Lymphocyte Activation; D008970:Molecular Weight
chemical_list: D001323:Autoantibodies; D001324:Autoantigens; D000939:Epitopes